Company Number: 15170008

Analysis Date: 2025-07-20 19:16 UTC

1. Credit Opinion: CONDITIONAL APPROVAL
   Corsenbio Consulting Ltd is a newly incorporated micro-entity (incorporated in September 2023) operating in biotechnology research, with minimal financial history. The company shows a positive net current asset position (£694) but reports a small negative net asset value (-£63) due to accruals exceeding total assets. The presence of only two employees and micro-entity sized accounts limits detailed financial insight. Given the early stage of the business and limited track record, credit approval can be considered but should be conditional on regular monitoring and potentially secured lending to mitigate risk.

2. Financial Strength:
   Balance sheet strength is currently weak. Fixed assets (£167) are negligible, and the company relies mainly on current assets (£20,555). Current liabilities (£19,861) are nearly equal to current assets, resulting in a tight working capital position. The slight negative net equity (-£63) suggests initial start-up costs or timing differences in accruals. No long-term debt or financial commitments are reported, which limits solvency risk but also reflects limited capital structure. As a micro-entity, it likely has minimal financial reserves.

3. Cash Flow Assessment:
   Liquidity appears narrowly positive with net current assets of £694, indicating the company can cover short-term obligations but with little margin. Cash or cash equivalents specifics are not disclosed but are presumably part of current assets. Working capital is tight, which could stress operations if revenue generation or receivables collection falters. Given the early stage, cash flow volatility is expected. The absence of audit and detailed profit and loss data limits visibility on operational cash flow generation.

4. Monitoring Points:

• Regular review of updated financial statements to track net asset progression and liquidity changes.
• Monitoring of cash flow and receivables collection to ensure operating expenses are met timely.
• Watch for any emerging debt or financial commitments that could strain liquidity.
• Management’s ability to secure additional funding or investment to support growth.
• Directors’ ongoing involvement and governance, particularly given the controlling PSC with significant voting rights.